Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind

Investors Await Additional Proof Points

 
• By Mandy Jackson
  
Biopharma stock valuations are beginning to recover, but cell and gene therapy firms are lagging (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Scrip